Medicare Administrative Contractor Palmetto GBA has expanded local coverage determination of Guardant Health’s (GH +0.5%) Guardant360 liquid biopsy assay to include its use across the majority of advanced solid tumors.
The updated policy covers the test for all fee-for-service Medicare beneficiaries with advanced cancers who meet the clinical criteria for complete genomic profiling with next-gen sequencing of tumor tissue to optimize treatment selection but lack available tissue for molecular profiling.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.